Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
Mori K., Kimura S., Parizi M. K., Enikeev D. V., Gly'bochko P. V., Seebacher V., Fajkovic H., Mostafaei H., Lysenko I., Janisch F., Egawa S., Shariat Sh.
Clinical genitourinary cancer.
Vol.17, Issue6, P. 409-418
Опубликовано: 2019
Тип ресурса: Обзор
DOI:10.1016/j.clgc.2019.07.009
Аннотация:
The purpose of this study was to assess the prognostic value of lactate dehydrogenase (LDH) in patients with metastatic prostate cancer (PC). A systematic review and meta-analysis was performed in March 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared patients with PC with high versus low LDH to determine the predictive value of LDH for overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS). We performed a formal meta-analysis for both OS and PFS. A total of 59 articles with 14,851 patients were included in the systematic review and 45 studies with 12,224 patients for the qualitative assessment. High LDH was associated with both worse OS (pooled hazard ratio [HR], 2.07; 95[%] confidence interval [CI], 1.75-2.44) and PFS (pooled HR, 1.08; 95[%] CI, 1.01-1.16). In subgroup analyses of both patients with castration-resistant prostate cancer (CRPC) and those with
Ключевые слова:
Castration-resistant prostate cancer (CRPC); Hormone-sensitive prostate cancer (HSPC); Lactate dehydrogenase (LDH); Meta-analysis; Metastatic prostate cancer
androgen receptor; docetaxel; lactate dehydrogenase; lactate dehydrogenase; tumor marker; cancer chemotherapy; cancer growth; cancer mortality; cancer prognosis; cancer specific survival; cancer survival; castration resistant prostate cancer; human; lactate dehydrogenase blood level; metastasis; metastatic prostate cancer; overall survival; predictive value; prognostic assessment; progression free survival; prostate cancer; qualitative analysis; Review; shared decision making; systematic review; blood; clinical decision making; disease exacerbation; enzymology; male; meta analysis; mortality; prognosis; prostate tumor; survival analysis; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Humans; L-Lactate Dehydrogenase; Male; Mortality; Prognosis; Prostatic Neoplasms; Survival Analysis
Язык текста: Английский
ISSN: 1938-0682
Mori K.
Kimura S.
Parizi M. K.
Enikeev D. V. Dmitrij Viktorovich 1982-
Gly'bochko P. V. Petr Vitalyevich 1964-
Seebacher V.
Fajkovic H.
Mostafaei H.
Lysenko I.
Janisch F.
Egawa S.
Shariat Sh. Sharokh 1973-
Мори К.
Кимура С.
Паризи М. К.
Еникеев Д. В. Дмитрий Викторович 1982-
Глыбочко П. В. Петр Витальевич 1964-
Сеебачер В.
Файковиc Х.
Мостафаеи Х.
Лyсенко И.
Йанисч Ф.
Егаwа С.
Шариат Ш. Шарох 1973-
Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis
Текст визуальный непосредственный
Clinical genitourinary cancer.
Cancer Information Group
Vol.17, Issue6 P. 409-418
2019
Обзор
Castration-resistant prostate cancer (CRPC) Hormone-sensitive prostate cancer (HSPC) Lactate dehydrogenase (LDH) Meta-analysis Metastatic prostate cancer
androgen receptor docetaxel lactate dehydrogenase lactate dehydrogenase tumor marker cancer chemotherapy cancer growth cancer mortality cancer prognosis cancer specific survival cancer survival castration resistant prostate cancer human lactate dehydrogenase blood level metastasis metastatic prostate cancer overall survival predictive value prognostic assessment progression free survival prostate cancer qualitative analysis Review shared decision making systematic review blood clinical decision making disease exacerbation enzymology male meta analysis mortality prognosis prostate tumor survival analysis Biomarkers, Tumor Clinical Decision-Making Disease Progression Humans L-Lactate Dehydrogenase Male Mortality Prognosis Prostatic Neoplasms Survival Analysis
The purpose of this study was to assess the prognostic value of lactate dehydrogenase (LDH) in patients with metastatic prostate cancer (PC). A systematic review and meta-analysis was performed in March 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis statement. Studies were deemed eligible if they compared patients with PC with high versus low LDH to determine the predictive value of LDH for overall survival (OS), cancer-specific survival (CSS), and progression-free survival (PFS). We performed a formal meta-analysis for both OS and PFS. A total of 59 articles with 14,851 patients were included in the systematic review and 45 studies with 12,224 patients for the qualitative assessment. High LDH was associated with both worse OS (pooled hazard ratio [HR], 2.07; 95[%] confidence interval [CI], 1.75-2.44) and PFS (pooled HR, 1.08; 95[%] CI, 1.01-1.16). In subgroup analyses of both patients with castration-resistant prostate cancer (CRPC) and those with